Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascendis Pharma A/S (ASND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Ascendis files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which include clinical, regulatory, financial, and corporate information related to its TransCon-based therapies.
In these filings, investors can review details on Ascendis’ pharmaceutical preparation manufacturing activities, including revenue from commercial products such as YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency. Unaudited condensed consolidated interim financial statements, management’s discussion and analysis, and segment information by geography (North America, Europe, and rest of world) are typically included in quarterly 6-K submissions.
Filings also describe the status of key pipeline programs like TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in oncology, along with updates on regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Additional 6-Ks may cover warrant grants, share capital changes, and the operation of equity compensation plans and share repurchase programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 20-F and 6-K filings, helping users quickly understand revenue drivers, operating results, and key clinical or regulatory events. Real-time updates from EDGAR ensure that new Ascendis filings, including financial statements and other material disclosures, are available promptly, while structured access makes it easier to locate specific reports relevant to ASND analysis.
Ascendis Pharma A/S reported strong growth for Q4 and full-year 2025, driven mainly by its endocrine products YORVIPATH and SKYTROFA. Q4 2025 product revenue was €240 million, and full-year 2025 product revenue reached €684 million. Total revenue for 2025 was €720 million, up from €364 million in 2024.
The company generated a Q4 2025 operating profit of €10 million and operating cash flow from operating activities of €73 million, but still posted a full-year net loss of €228 million, improved from a €378 million loss in 2024. Cash and cash equivalents were €616 million as of December 31, 2025. TransCon CNP is under FDA Priority Review with a PDUFA action goal date of February 28, 2026, and management aspires to about €500 million in operating cash flow in 2026 and at least €5 billion in global annual product revenue by 2030.
Ascendis Pharma A/S files its annual Form 20-F, highlighting continued investment-led losses and a growing commercial footprint in endocrinology and oncology. The company markets once-weekly growth hormone SKYTROFA and hypoparathyroidism therapy YORVIPATH in the U.S. and Europe, and is advancing additional TransCon-based candidates.
Ascendis reported a net loss of €228 million for 2025, versus €378.1 million for 2024, and a total equity deficit of €162.8 million at December 31, 2025. Cash and cash equivalents totaled €616 million, which management believes can fund operations for at least twelve months. As of December 31, 2025, there were 61,977,408 ordinary shares outstanding, including ADSs held by the company and subsidiaries.
The filing emphasizes heavy reliance on TransCon technologies, significant ongoing R&D and commercialization spending, potential need for additional financing, and extensive risk factors ranging from intense competition and regulatory uncertainty to manufacturing, reimbursement, cybersecurity, geopolitical and macroeconomic pressures.
Ascendis Pharma A/S received an amended ownership report showing that Westfield Capital Management Company, L.P. beneficially owns 5,185,696 shares of Ascendis common stock, representing 8.48% of the class as of 12/31/2025.
Westfield has sole power to vote 4,244,766 shares and sole power to dispose of 5,185,696 shares. The shares are owned of record by Westfield’s investment advisory clients, who receive dividends and sale proceeds. Westfield states the holdings are in the ordinary course of business and not for influencing control.
Ascendis Pharma A/S reports that its board granted an aggregate of 16,570 warrants to certain employees on February 10, 2026 under Appendix 1a of its Articles of Association. Each warrant allows the holder to subscribe for one ordinary share at an exercise price of US $224.19 per share, matching the closing price of the company’s ADS on the grant date.
Vesting is service-based, with 25% of the warrants vesting on the one-year anniversary of the grant and the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and possible earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,666,633 shares remain available for future grants under the Articles of Association.
Artisan Partners has disclosed a significant institutional stake in Ascendis Pharma A/S. Through several affiliated entities, it reports beneficial ownership of 3,225,885 American Depositary Shares, representing 5.2% of the class, based on 61,977,408 shares outstanding as of 12/30/2025.
Artisan Partners has shared voting power over 2,883,433 shares and shared dispositive power over 3,225,885 shares. The shares are held on behalf of discretionary clients of Artisan Partners Limited Partnership, which receive dividends and sale proceeds. The filing states the holdings are in the ordinary course of business and not for changing or influencing control of Ascendis Pharma.
Ascendis Pharma A/S reports that its board granted 42,030 new warrants to certain employees on 13 January 2026 under Appendix 1a of its Articles of Association. Each warrant gives the right to buy one ordinary share at an exercise price of US $215.05 per share, matching the closing price of the company’s ADSs on the grant date.
These warrants vest over time: 25% after one year, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and possible earlier vesting upon specified exit events. After this grant, warrants to subscribe for an additional 1,683,203 shares remain available for future grants under the Articles of Association, which have been amended to reflect the new issuance.
Ascendis Pharma A/S shareholder Jan Mikkelsen has filed a Form 144 notice to sell 86,860 American Depositary Shares on Nasdaq through Citigroup Global Markets. These ADS were acquired on 01/13/2026 through a restricted stock and performance stock unit compensation program, with the same date listed for acquisition and payment, and compensation noted as the nature of payment.
The notice also reports that during the past three months, Mikkelsen sold 100,000 American Depositary Shares on 12/02/2025, generating gross proceeds of 20675000.00. The filing states that the person on whose behalf the securities are to be sold represents that they do not know any material adverse information about Ascendis Pharma A/S that has not been publicly disclosed.
Ascendis Pharma A/S reports that it has provided a business and strategic roadmap update, outlining planned key corporate milestones for 2026 across its pipeline, including products such as TransCon PTH, TransCon CNP, TransCon hGH, TransCon IL-2 β/γ and TransCon aVEGF, as well as its collaboration on TransCon semaglutide.
The Board of Directors has also authorized a $120 million share repurchase program. Repurchases may be made from time to time in the open market, through privately negotiated transactions, or by other methods permitted under applicable securities laws. The company is not obligated to buy back a specific number of shares, and the program may be modified, suspended or terminated at any time without notice.
The company emphasizes that these plans and milestones are forward-looking and subject to significant risks and uncertainties, including regulatory, clinical, manufacturing, commercial, financial and geopolitical factors described in its SEC reports.
Ascendis Pharma A/S reported topline Week 52 results from COACH, its first Phase 2 trial testing once-weekly TransCon CNP and TransCon hGH combination therapy in children with achondroplasia. The company states that combination treatment showed durable growth over 52 weeks without compromising safety or tolerability, and that it also improved body proportionality and arm span in line with increased linear growth. Reported safety and tolerability were consistent with prior monotherapy experience and treatment-emergent adverse events were generally mild. TransCon CNP is under Priority Review by the U.S. FDA with a PDUFA target action date of February 28, 2026, and Ascendis has already held an end of Phase 2 meeting with the FDA regarding a planned Phase 3 pediatric achondroplasia trial.
Ascendis Pharma A/S reports that the U.S. Food and Drug Administration has classified new information it submitted on November 5, 2025 for TransCon CNP (navepegritide) as a major amendment to its New Drug Application for treating children with achondroplasia. Because of this, the FDA has extended the PDUFA target action date by three months to February 28, 2026. This change gives the FDA more time to complete its ongoing review before deciding on the application.